Sonova to present at the J.P. Morgan 2025 Healthcare Conference
Werte in diesem Artikel
Sonova Holding AG
/ Key word(s): Conference
Werbung Werbung Group Media & Investor Release Staefa (Switzerland), January 13, 2025 – Sonova Holding AG (SWX: SOON), a leading provider of innovative hearing solutions, announces that its Chief Executive Officer Arnd Kaldowski will today present Sonova’s strategy and an overview of the current business dynamics at the J.P. Morgan 2025 Healthcare Conference in San Francisco, California. The presentation will take place on Monday, January 13, 2025, at 07:30pm Central European Time (CET) / 10:30am US Pacific Standard Time (PST). Presentation slides will be available at: https://www.sonova.com/en/investor-presentations. Arnd Kaldowski, CEO of Sonova, says: “We are encouraged by the positive trends in each of our four Sonova business units and are pleased to present at the J.P. Morgan Healthcare Conference. Notably, we continue to see a strong reception for our new Phonak Infinio and Phonak Sphere Infinio platforms as well as improved sales momentum in our Audiological Care business as we have moved into the second half of our financial year. Based on these developments, we reaffirm our guidance for the fiscal year, reflecting our commitment to delivering sustained growth and value to our shareholders.” Werbung Werbung – End – About Sonova Sonova operates through four businesses – Hearing Instruments, Audiological Care, Consumer Hearing and Cochlear Implants – and the core brands Phonak, Unitron, AudioNova, Sennheiser (under license) and Advanced Bionics as well as recognized regional brands. The Group’s globally diversified sales and distribution channels serve an ever growing consumer base in more than 100 countries. In the 2023/24 financial year, the Group generated sales of CHF 3.6 billion, with a net profit of CHF 610 million. Over 18,000 employees are working on achieving Sonova’s vision of a world where everyone enjoys the delight of hearing. For more information please visit www.sonova.com. Disclaimer
End of Media Release |
Language: | English |
Company: | Sonova Holding AG |
Laubisrütistrasse 28 | |
8712 Stäfa | |
Switzerland | |
Phone: | +41 58 928 33 33 |
E-mail: | ir@sonova.com |
Internet: | www.sonova.com |
ISIN: | CH0012549785 |
Valor: | 12549785 |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2066739 |
End of News | EQS News Service |
|
2066739 13.01.2025 CET/CEST
Ausgewählte Hebelprodukte auf Sonova
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sonova
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Sonova AG
Analysen zu Sonova AG
Datum | Rating | Analyst | |
---|---|---|---|
22.02.2013 | Sonova kaufen | Vontobel Research | |
12.02.2013 | Sonova kaufen | Vontobel Research | |
04.12.2012 | Sonova overweight | Morgan Stanley | |
23.11.2012 | Sonova kaufen | Fuchsbriefe | |
14.11.2012 | Sonova neutral | UBS AG |
Datum | Rating | Analyst | |
---|---|---|---|
22.02.2013 | Sonova kaufen | Vontobel Research | |
12.02.2013 | Sonova kaufen | Vontobel Research | |
04.12.2012 | Sonova overweight | Morgan Stanley | |
23.11.2012 | Sonova kaufen | Fuchsbriefe | |
14.11.2012 | Sonova overweight | J.P. Morgan Cazenove |
Datum | Rating | Analyst | |
---|---|---|---|
14.11.2012 | Sonova neutral | UBS AG | |
13.11.2012 | Sonova neutral | Sarasin Research | |
07.11.2012 | Sonova equal-weight | Morgan Stanley | |
22.10.2012 | Sonova neutral | Sarasin Research | |
05.10.2012 | Sonova neutral | Sarasin Research |
Datum | Rating | Analyst | |
---|---|---|---|
14.11.2012 | Sonova underperform | Exane-BNP Paribas SA | |
12.11.2012 | Sonova underperform | Exane-BNP Paribas SA | |
10.10.2012 | Sonova underperform | Exane-BNP Paribas SA | |
27.09.2012 | Sonova underperform | Exane-BNP Paribas SA |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sonova AG nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen